Patent Application
20140180248
Not Applicable
The present invention is in the technical field of medical devices. More particularly, the present invention relates to tissue ablation, in particular vascular ablation by chemical means.
Lower extremity chronic venous disorder (CVD) is a medical condition affecting up to 50% of all Americans. The spectrum of CVD ranges from varicose veins and telangiectasias, which can be symptomatic and unsightly, to severe edema, skin ulceration and ultimately major disability. This condition is most often caused by venous hypertension induced by incompetent valves in the superficial veins of the leg. Incompetent valves, which lead to venous hypertension, most commonly occur in the great saphenous vein (GSV), but can also occur in the small saphenous vein (SSV), and in any of a multitude of perforator veins which communicate between the deep and superficial venous systems of the leg.
The traditional therapy for treatment of varicose veins dates back to the ancient Greek, who described a method of surgical ligation and stripping of varicose veins. Surgical ligation and stripping remained the mainstay of varicose vein treatment until the more recent introduction of endovascular techniques for saphenous vein ablation. These techniques, which utilize laser or radiofrequency energy delivered through endovascular techniques, have been shown to result in shorter recovery time, fewer complications, and more durable results when compared to traditional ligation and stripping. Current treatments for CVD resulting from superficial venous insufficiency include surgical ligation and stripping, injection sclerotherapy, and endovenous ablation using laser or radiofrequency energy, or any combination of the above.
Although the introduction of endovascular techniques represented a significant advancement in the treatment of venous insufficiency, there are several shortcomings. The energy deposited by the laser or radiofrequency probe, although effective at ablating the target vein, has the potential to damage adjacent structures including nerves, muscle, fat and overlying skin. To minimize this risk, most practitioners use tumescent anesthesia—a lidocaine and saline solution deposited around the target vein that acts as an insulator between the ablation catheter and surrounding structures. Most often the tumescent anesthesia is delivered through a needle which is advanced under ultrasound guidance, and most often requires multiple needle punctures. This process is not only painful and time consuming, but also introduces the risk of lidocaine toxicity secondary to inadvertent intravenous injection, and infection secondary to multiple punctures.
Injection sclerotherapy is another non-surgical alternative to surgical stripping. Sclerotherapy involves the injection of a sclerosing agent which results in chemical ablation of the venous endothelium. Sclerosants such as hypertonic saline cause dehydration and cell membrane denaturation along the venous endothelium. Sclerosants such as polidocanol and sodium tetradecyl sulfate are week detergents that disrupt the endothelial cellular membrane. Delivery of these sclerosants, which are typically injected as a liquid, is inherently inaccurate. Excessive injection of sclerosant can cause the solution to propagate into the deep venous system, and therefore increases the risk of deep vein thrombosis; conversely, insufficient volume will fail to sclerose the target vessel. In addition, extravasation of sclerosant can be painful and potentially damaging to surrounding tissue.
A device which would allow for precise, reliable tissue ablation without threat of injury to surrounding tissue would represent a significant improvement in the state of the art for the treatment of venous insufficiency, as well as for tissue ablation elsewhere in the body.
Forward osmosis is a process that uses a semi-permeable membrane to effect separation of water from dissolved solutes. The driving force for this separation is an osmotic pressure gradient, such that a “draw” solution of high concentration (relative to that of the “feed” solution), is used to induce a net flow of water through the membrane into the draw solution, thus effectively separating the feed water from its solutes. The simplest equation describing the relationship between osmotic and hydraulic pressures and water flux is: Jw=A(Δπ−ΔP) where Jw is water flux, A is the hydraulic permeability of the membrane, Δπ is the difference in osmotic pressures on the two sides of the membrane, and ΔP is the difference in hydrostatic pressure (negative values of Jw indicating reverse osmotic flow).
The present invention describes a balloon catheter, or other catheter with an expandable element along the distal aspect, where the expandable element is comprised in part or in whole of a semipermeable membrane. The balloon is insufflated with a hyperosmolar (relative to cytoplasm) draw solution until the balloon contacts the tissue to be ablated, for example the vessel endothelium. The osmotic pressure gradient between the intracellular cytoplasm and balloon lumen results in flux of water across the cell membrane and semipermeable membrane of the balloon, into the balloon lumen. This would result in cellular dehydration and cell membrane desiccation, similar to that induced by intravascular injection of hypertonic saline. Any crystalloid or colloid hyperosmolar solution, or any hygroscopic material, that would affect the flow of water across the membrane may be used.
In addition to the permeability characteristics of the membrane, the balloon would ideally, but not necessarily, be constructed from a highly compliant material that would keep the internal pressure of the balloon low, and thereby facilitate forward osmosis across the balloon. A compliant balloon would also allow for improved apposition between the balloon and target tissue along tortuous segments and varying diameters of the vessel. Alternatively, a non-compliant material could be used if it provides more favorable permeability characteristics, with the geometry of the balloon or balloons altered to improve tissue apposition and water flux across the membrane.
Although the invention is discussed with specific reference to venous ablation in the treatment of venous insufficiency, the invention is contemplated to have wider applications. For example (but not limited to), the device can be used to achieve sclerosis of the gonadal vein in the treatment of varicocele or pelvic congestion syndrome, sclerosis of fallopian tubes in lieu of tubal ligation, ablation of the uterine endometrium for the treatment of dysfunctional uterine bleeding, or in sclerosis of pulmonary veins in the treatment of arrhythmias or pulmonary arteriovenous malformations. In addition, the device can be used to induce osmotic damage to renal sympathetic nerves as a potential treatment for resistant hypertension. The properties of the balloon membrane and insufflating solution, as well as the balloon geometry, could be altered in accordance with need. For example, the balloon can be filled with a hypotonic solution, to allow flux of fluid out of the balloon.
An embodiment of the present invention is illustrated in
As illustrated in
While the foregoing written description of the invention enables one of ordinary skill to make use what is considered presently to be the best mode thereof, those of ordinary skill will understand and appreciate the existence of variations, combinations, and equivalents of the specific embodiment, method and examples herein. The invention should therefore not be limited by the above described embodiments, methods and/or examples, but by all embodiments and methods within the scope and spirit of the invention as claimed.
This application claims priority to provisional application No. 61/580,261 filed Dec. 26, 2011.
